Mazor Robotics Ltd. (NASDAQ: MZOR) is watching its shares rise handily on Monday after the company announced that it has received the first pre-launch orders for its guidance platform for spine surgeries. The Mazor X…
IntelliPharmaCeutics International Inc. (NASDAQ: IPCI) is watching its shares jump on Monday after the company announced that it received a tentative approval from the U.S. Food and Drug Administration. Specifically, the tentative approval was…
Shares of EpiPen maker Mylan NV (NASDAQ: MYL) rose nearly 12.5% early Monday following the company’s announcement after markets closed Friday that it had reached an agreement with the U.S. Department of Justice to…
Several analysts have weighed in with higher price targets on top of their ratings for Tesaro. Its shares hit a new 52-week high on Monday.
On Monday morning, Merck, Mylan and Bristol-Myers Squibb made substantial runs, either up or down.
Shares of Exelixis saw a handy gain early Monday morning after the company reported positive results from its mid-stage trial for the treatment of renal cell carcinoma.
CRISPR Therapeutics expects to price more than 4 million shares in the range of $15 to $17 apiece for an initial public offering valued up to nearly $92 million.
courtesy of Mylan Specialty L.P.From The Fiscal Times What happens when a major drug maker that does business with the government has been caught price gouging consumers? Executives at Health and Human Services sift…
Shares of Idera Pharmaceuticals sank on Thursday after the company announced that it intends to have a secondary offering.
Alnylam Pharmaceuticals saw its shares crash on Thursday after the company announced that it will be discontinuing one of its late-stage trials.
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) has been on a meteoric rise over the past month. In this time the stock has gained over 150%, on what has been relatively little news for such a…
In a new research report from Jefferies, many of the outstanding companies in pharmaceuticals and biotech space show up among the stocks to buy.
Scynexis shares made a handy gain early on Thursday after the company announced the results from a couple of its mid-stage trials.
24/7 Wall St. has collected several big FDA decisions and mid- to late-stage trials that should be coming up in November and December.
Shares of Immunomedics dropped sharply on Wednesday after the company announced the pricing of its secondary offering.
